Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Stat5a/b Inhibitor
IST5-002 is a selective inhibitor of Stat5a and Stat5b, with IC50 values of 1.5 μM and 3.5 μM, respectively. This compound effectively disrupts the transcriptional activity of Stat5 proteins, inducing apoptosis in prostate cancer and chronic myeloid leukemia (CML) cells. IST5-002 is suitable for research applications focused on understanding the role of Stat5 in cancer progression and therapeutic targeting in prostate cancer and CML. -
STAT3 Inhibitor
Danvatirsen is an antisense oligonucleotide that specifically inhibits STAT3, a transcription factor involved in cell survival and proliferation. This compound reduces cell viability and promotes apoptosis in leukemia cell lines, while downregulating the expression of endogenous STAT3 and its downstream target genes. Additionally, Danvatirsen effectively diminishes proliferation and tumorigenicity in models of neuroblastoma and lymphoma. In vivo studies demonstrate its capacity to inhibit tumor growth rates in mouse models of neuroblastoma, lymphoma, and non-small cell lung cancer. Danvatirsen is applicable in research focused on lymphoma, myelodysplastic syndrome, acute myeloid leukemia, and neuroblastoma. -
STAT3 Inhibitor
HP590 is a potent, orally active inhibitor of STAT3, demonstrating an IC50 of 27.8 nM for STAT3 luciferase activity and 24.7 nM for ATP inhibition. This compound exhibits significant anti-proliferative effects on gastric cancer cells and effectively induces apoptosis. HP590 serves as a valuable research tool for investigating the role of STAT3 in cancer biology and potential therapeutic interventions. -
STAT3 Signal Inhibitor
STAT3-IN-12 is a potent inhibitor of the STAT3 signaling pathway, effectively blocking IL-6 induced JAK/STAT3 activation. This compound exhibits significant anti-cancer activity by inhibiting cell growth, reducing migration, promoting apoptosis, and inducing cell cycle arrest. STAT3-IN-12 is particularly relevant for research applications in cancers such as hepatocellular carcinoma (HCC) and esophageal carcinoma. -
STAT3 Phosphorylation Inhibitor
Tetramethylcurcumin is a selective inhibitor of STAT3 phosphorylation, targeting Janus kinase 2 and the Src homology-2 domain of STAT3. This compound demonstrates significant anti-inflammatory and anti-cancer properties, making it a valuable tool for research into cancer biology and inflammatory pathways. Its ability to modulate key signaling events provides insight into therapeutic strategies for diseases driven by aberrant STAT3 activity. -
STAT3 Inhibitor
STAT3-IN-11 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3), specifically targeting the phosphorylation at Tyr705. This compound downregulates the phosphorylation of downstream genes such as Survivin and Mcl-1, while leaving upstream tyrosine kinases like Src and JAK2 unaffected. By inducing apoptosis in cancer cells, STAT3-IN-11 presents potential as a valuable tool for research in cancer therapeutics and the development of effective STAT3 inhibitors. -
AKR1C1/JAK2/STAT3/NF-κB Inhibitor
Zingiberen Newsaponin is a potent inhibitor of the AKR1C1/JAK2/STAT3 and NF-κB signaling pathways. This steroid saponin compound demonstrates significant anti-hepatocellular carcinoma (HCC) activity by promoting cancer cell apoptosis through the induction of oxidative stress, as evidenced by the upregulation of ROS and MDA levels. Additionally, Zingiberen Newsaponin mitigates cerebral ischemia-reperfusion injury by reducing pro-inflammatory cytokines and enhancing superoxide dismutase (SOD) activity, thereby protecting neuronal cells. Furthermore, it has been shown to induce platelet aggregation, broadening its application in cardiovascular research. -
STAT3-SH2 Domain Inhibitor
STAT3-SH2 Domain Inhibitor 1 specifically targets the Src Homology 2 (SH2) domain of STAT3, exhibiting a Kd value of 1.57 μM. This compound effectively inhibits STAT3 signaling and transcriptional activation, leading to apoptosis in gastric cancer cells. It serves as a valuable tool for researching mechanisms of cancer progression and potential therapeutic strategies targeting the STAT3 pathway. -
STAT3 Inhibitor
8-Epixanthatin is a STAT3 inhibitor derived from Xanthium chinese Mill. It effectively inhibits STAT3 activation, leading to the induction of apoptosis in cancer cells. This compound demonstrates notable anti-tumor activity, making it a valuable tool for research applications focused on cancer biology and therapeutic development. -
STAT3 Inhibitor
WB436B is a selective inhibitor of STAT3, targeting STAT3-Tyr705 phosphorylation and modulating the expression of downstream STAT3 target genes. This compound exhibits significant cytotoxicity against pancreatic cancer cells while promoting apoptosis. In preclinical mouse models, WB436B has been shown to suppress tumor growth and metastasis, leading to an extended survival rate in tumor-bearing subjects. This makes WB436B a valuable tool for research in cancer biology and therapeutic development. -
STAT3 Inhibitor
HJC0416 hydrochloride is a potent inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) that exhibits enhanced anticancer properties compared to Stattic. This compound has demonstrated significant biological activity against breast cancer, making it a promising candidate for cancer research applications. Its oral bioavailability and efficacy highlight its potential as a valuable tool for investigating STAT3-related pathways in oncology. -
STAT3 Inhibitor
SC99 is a selective inhibitor of the STAT3 pathway, exerting its effects through the inhibition of JAK2. By binding to the ATP-binding pocket of JAK2, SC99 effectively prevents the phosphorylation of both JAK2 and STAT3, while sparing other kinases linked to STAT3 signaling. SC99 demonstrates significant biological activity, including the inhibition of platelet activation and aggregation, as well as potent anti-myeloma and anti-thrombotic effects, making it a valuable tool for research in cancer and cardiovascular studies. -
STAT3 Inhibitor
LLL3 is a potent STAT3 inhibitor that effectively impedes the dimerization and phosphorylation of STAT3, thereby blocking its translocation into the nucleus. This mechanism leads to reduced expression of STAT3-dependent genes, including those encoding Bcl-xL and cyclin D1. Moreover, LLL3 has been shown to induce growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells through the activation of the caspase pathway. This reagent is valuable for investigating cancers associated with persistent STAT3 activation. -
STAT5b Inhibitor
Pomstafib-2 is a potent and selective inhibitor of STAT5b, a transcription factor involved in various signaling pathways. This compound reduces the expression of phosphorylated STAT5b (pSTAT5b) and promotes apoptotic processes in cells. Pomstafib-2 is valuable for studying STAT5b-related biological functions and developing therapies targeting STAT5b-driven malignancies. -
JAK2/STAT3/NF-κB Inhibitor
Reticuline acts as a JAK2/STAT3 and NF-κB signaling pathway inhibitor, displaying notable anti-inflammatory properties. It effectively downregulates the mRNA expression of pro-inflammatory cytokines such as TNF-α and IL-6 while also reducing the phosphorylation levels of JAK2 and STAT3. Additionally, Reticuline demonstrates potential cardiovascular effects, making it a valuable tool for research in inflammation and cardiovascular studies. -
JAK2/STAT3 Inhibitor
SD-1029 is a selective JAK2/STAT3 inhibitor that impedes the phosphorylation of JAK2, thereby obstructing STAT3 activation. By inhibiting STAT3 nuclear translocation, SD-1029 serves as a valuable tool for studying the JAK2/STAT3 signaling pathway. This compound is relevant in research applications involving cancer, autoimmune disorders, and other diseases associated with dysregulated STAT3 activity. -
JAK2/STAT3 Pathway Inhibitor
WP1193 is a potent inhibitor of the JAK2/STAT3 signaling pathway. It effectively suppresses the phosphorylation of both JAK2 and STAT3, leading to a decrease in the expression of key stem cell markers such as CD133 and c-myc. This compound is valuable for research into glioblastoma and other cancers associated with aberrant activation of the JAK2/STAT3 pathway. -
JAK/STAT Inhibitor
JAK-STAT-IN-1 is a selective inhibitor of the JAK-STAT signaling pathway. This compound exhibits potent inhibitory activity, making it a valuable tool in the investigation of autoimmune disorders. Its specificity for JAK-STAT modulation facilitates research into the underlying mechanisms of inflammation and immune response regulation. -
Multi-kinase Inhibitor
Debio 0617B is a multi-kinase inhibitor that targets key kinases involved in the regulation of STAT3/STAT5 signaling, including JAK, SRC, ABL, and class III/V receptor tyrosine kinases. This compound effectively reduces the maintenance and self-renewal of primary human acute myeloid leukemia (AML) CD34+ stem/progenitor cells. Additionally, Debio 0617B has demonstrated efficacy in preclinical models of STAT3-driven solid tumors, making it a valuable tool for cancer research and therapeutic development. -
PTPN2/1 Dual Inhibitor
PTPN2/1-IN-4 is a potent dual inhibitor of PTPN1 and PTPN2, exhibiting IC50 values of 12.8 nM and 5.8 nM, respectively. This compound effectively modulates the IFNγ-JAK-STAT signaling pathway, resulting in enhanced CD8+ T-cell infiltration into tumors. PTPN2/1-IN-4 demonstrates significant anticancer activity, inhibiting tumor growth both as a standalone treatment and in combination with anti-PD-1 antibodies in B16-OVA syngeneic mouse models, making it a valuable tool for cancer research. -
BFAR Inhibitor
iBFAR2 is a selective inhibitor of the BFAR protein, targeting its role in immune modulation. This compound effectively restores the CD8+ tissue-resident memory T (TRM) cell subset, enhancing anti-tumor immunity in solid tumors. iBFAR2 promotes the association between JAK2 and STAT1 as well as the subsequent phosphorylation of STAT1, contributing to its biological activity in cancer research applications. -
JAK2/STAT3 Iinhibitor
HD-2a is a JAK2/STAT3 inhibitor that functions by downregulating circDcbld2 expression in RAW264.7 cells. This compound is valuable for research into the modulation of the JAK2/STAT3 signaling pathway, which is implicated in various inflammatory and autoimmune disorders. HD-2a can aid in the exploration of therapeutic strategies targeting JAK2/STAT3-mediated processes. -
STAT3 Inhibitor
LY5 is a potent inhibitor of STAT3, exhibiting an IC50 of 0.5 μM. It induces apoptosis and effectively inhibits STAT3 phosphorylation, demonstrating significant antitumor activity in vivo. This compound is utilized in cancer research to explore the mechanisms of STAT3-related signaling pathways and their implications in tumorigenesis. -
STAT3 Inhibitor
HJC0123 is a potent STAT3 inhibitor that effectively suppresses the proliferation of hepatic stellate cells while inducing cell cycle arrest and apoptosis. It reduces STAT3 phosphorylation, nuclear translocation, and transcriptional activity, leading to increased IL-6 production and inhibition of Smad2/3 phosphorylation, along with down-regulation of SOCS3. HJC0123 serves as a valuable tool for investigating liver fibrosis and related pathways. -
STAT3 Inhibitor
STAT3-IN-38 is a selective inhibitor of the signal transducer and activator of transcription 3 (STAT3) protein, exhibiting a KD value of 45.33 µM. By binding to the SH2 domain of STAT3, it effectively inhibits phosphorylation at the pTyr705 site, leading to the downregulation of downstream genes such as Survivin and Mcl-1. This compound has demonstrated the ability to block cell-cycle progression and induce apoptosis in colorectal cancer cells, making it a valuable tool for cancer research and therapeutic development. -
IKK/STAT3 Dual Inhibitor
ACHP is a selective IκB kinase (IKK) and STAT3 dual inhibitor, demonstrating potent inhibitory activity with IC50 values of 8.5 nM and 250 nM for IKKβ and IKKα, respectively. It effectively disrupts the STAT3 signaling pathway, leading to cancer cell cycle arrest and apoptosis. Additionally, ACHP exhibits significant anti-inflammatory properties in preclinical models, such as the mouse ear edema model. This compound is a valuable tool for research in anti-inflammatory and anti-cancer studies, including applications in multiple myeloma and leukemia. -
HDAC3/p-STAT3 Inhibitor
1-Stearoyl-sn-glycero-3-phosphocholine is an inhibitor of histone deacetylase 3 (HDAC3) and the phosphorylation of signal transducer and activator of transcription 3 (p-STAT3). This compound has demonstrated the ability to induce apoptosis and exhibits significant anticancer activity in chronic myelogenous leukemia (CML) K562 cells. It serves as a valuable tool for researchers investigating the therapeutic potential of HDAC inhibitors in cancer treatment. -
STAT3/JAK Inhibitor
Brevilin A is a potent inhibitor of the STAT3/JAK signaling pathway, with an IC50 value of approximately 10.6 μM for STAT3. It exhibits anti-tumor properties and effectively inhibits the proliferation of cancer cells. Additionally, Brevilin A has been shown to induce both apoptosis and autophagy, making it a valuable tool for cancer research and therapeutic investigations. -
STAT6 Inhibitor
STAT6-IN-7 is a potent inhibitor of STAT6, effectively disrupting the binding of human STAT6 to phosphorylated IL-4 receptor alpha (pIL-4Rα) with an IC50 value of 0.28 μM. Its mechanism of action makes it a valuable tool in the study of inflammatory and allergic diseases, aiding researchers in elucidating the role of STAT6 in these pathological conditions. -
STAT6 Inhibitor
STAT6-IN-9 is a selective inhibitor of Signal Transducer and Activator of Transcription 6 (STAT6), demonstrating an EC50 value of 4 nM. This compound effectively interferes with STAT6 activation driven by the IL-13-IL-13 receptor/IL-4 receptor signaling pathway. Additionally, STAT6-IN-9 inhibits CCL17 secretion with an IC50 of 4.6 nM. It is a valuable tool for investigating chronic inflammatory diseases associated with STAT6 dysregulation, including allergies, asthma, and chronic obstructive pulmonary disease. -
STAT6 Inhibitor
STAT6-IN-10 is a potent inhibitor of signal transducer and activator of transcription 6 (STAT6), exhibiting an EC50 of 0.002 μM. This compound effectively inhibits the secretion of CCL17 in peripheral human whole blood with an IC50 of 0.095 μM, making it a valuable tool for studying inflammatory responses. STAT6-IN-10 is applicable in research focused on dermatological and respiratory conditions, providing insights into therapeutic interventions targeting these pathways. -
STAT6 Inhibitor
STAT6-IN-3 is a potent STAT6 inhibitor designed to selectively target the SH2 domain of STAT6, exhibiting a high binding affinity with an IC50 value of 0.04 μM. This compound is valuable in studying inflammatory processes, particularly in disorders such as asthma, by providing insights into the modulation of STAT6 signaling pathways. Researchers can utilize STAT6-IN-3 to explore its effects on cytokine signaling and immune response regulation. -
STAT3 Inhibitor
SI-109 is a potent inhibitor of the STAT3 SH2 domain, demonstrating an inhibitory constant (Ki) of 9 nM. This compound effectively reduces the transcriptional activity of STAT3 with an IC50 value of 3 μM. SI-109 is utilized in research applications involving antitumor activity and has been instrumental in the development of PROTAC STAT3 degrader SD-36, an important tool in targeted protein degradation studies. -
STAT6 Inhibitor
YM-341619 is a potent STAT6 inhibitor with an IC50 of 0.70 nM, demonstrating effective modulation of Th2 cell differentiation in mouse spleen T cells induced by IL-4, with an IC50 of 0.28 nM. This compound selectively inhibits Th2 differentiation without impacting Th1 cells, making it a valuable tool for research into allergic diseases, including allergic asthma. Its oral bioavailability enhances its utility in in vivo studies aimed at understanding the role of STAT6 signaling in immune responses. -
STAT6 Inhibitor
STAT6-IN-1 is a potent STAT6 inhibitor that specifically targets the SH2 domain of STAT6 with an IC50 value of 0.028 µM. This compound demonstrates significant biological activity in the modulation of signaling pathways associated with allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease, and various cancer types. STAT6-IN-1 is a valuable tool in research applications focused on elucidating the role of STAT6 in inflammatory and oncogenic processes. -
STAT6 Inhibitor
AS1810722 is a potent inhibitor of STAT6, exhibiting an IC50 of 1.9 nM. This compound possesses a favorable profile regarding CYP3A4 inhibition. As a derivative of fused bicyclic pyrimidine, AS1810722 is poised for research applications in allergic diseases, including asthma and atopic disorders. -
STAT6 Inhibitor
STAT6-IN-4 is a selective inhibitor of Signal Transducer and Activator of Transcription 6 (STAT6), exhibiting an IC50 value of 0.34 μM. This compound has significant potential in the study of inflammatory and allergic conditions, providing researchers the ability to investigate the roles of STAT6 in disease pathogenesis and therapeutic responses. Its application can aid in elucidating the molecular mechanisms underlying STAT6-mediated pathways. -
STAT6 Inhibitor
STAT6-IN-5 is a selective inhibitor of STAT6, demonstrating an IC50 value of 0.24 μM. This compound is primarily utilized in the investigation of inflammatory and allergic diseases, such as atopic dermatitis. Its efficacy in modulating STAT6 activity makes it a valuable tool for exploring therapeutic strategies in related biological pathways. -
STAT6 Inhibitor
STAT6-IN-2 is a selective inhibitor of STAT6, effectively blocking the tyrosine phosphorylation of this transcription factor. By inhibiting STAT6, it reduces the secretion of eotaxin-3, which is pivotal in the inflammatory response. This reagent is particularly valuable for research into immune diseases and allergic inflammatory conditions, including asthma, providing insights into the underlying mechanisms and potential therapeutic targets. -
STAT6 Inhibitor
PM-43I is a potent inhibitor of Signal Transducer and Activator of Transcription 6 (STAT6), effectively reducing its phosphorylation levels. This compound demonstrates significant biological activity in the modulation of immune responses and inflammatory pathways. PM-43I is applicable in research related to allergic lung diseases, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and cancer, making it a valuable tool for investigating STAT6-mediated mechanisms. -
STAT3 Inhibitor
LLL12 is a potent inhibitor of STAT3, specifically targeting its phosphorylation. By interfering with the STAT3 signaling pathway, LLL12 demonstrates significant anti-tumor activity, particularly enhancing the effects of Cisplatin and Paclitaxel on ovarian cancer cell proliferation, migration, and growth. This compound is valuable for research in cancer biology and therapeutic development, especially in exploring combinatorial treatment strategies. -
STAT5a Inhibitor
Stafia-1 is a selective inhibitor of STAT5a, exhibiting a Ki of 10.9 μM and an IC50 of 22.2 μM. It demonstrates significant selectivity for STAT5a over STAT5b and other members of the STAT family. This compound is valuable for research investigating the role of STAT5a in cellular signaling pathways and its implications in various diseases, including cancer and inflammation. -
STAT3 Dimerization Inhibitor
STX-0119 is a selective inhibitor of STAT3 dimerization, targeting the STAT3 signaling pathway. By inhibiting STAT3 transcription with an IC50 of 74 μM, STX-0119 effectively disrupts the aberrant activation of STAT3, which is implicated in various cancers and inflammatory diseases. This compound is valuable for research applications focused on understanding the role of STAT3 in tumorigenesis and potential therapeutic interventions. -
STAT3 Inhibitor
STAT3-IN-25 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). It exhibits significant inhibition of STAT3 luciferase activity in HEK293T cells, displaying an IC50 of 22.3 nM, and inhibits ATP production in BxPC-3 pancreatic cancer cells with an IC50 of 32.5 nM. This compound shows potential for use in research focused on pancreatic cancer and other conditions linked to aberrant STAT3 signaling. -
STAT5b SH2 Inhibitor
Stafib-1 is a selective inhibitor of the STAT5b SH2 domain, exhibiting a Ki value of 44 nM and an IC50 of 154 nM. It effectively disrupts STAT5b signaling, which plays a crucial role in various cellular processes, including proliferation and apoptosis. Stafib-1 is valuable for research applications aimed at understanding oncogenic signaling pathways and exploring potential therapeutic strategies for STAT5b-driven malignancies. -
STAT5b Inhibitor
Stafib-2 is a selective inhibitor of the transcription factor STAT5b, demonstrating an IC50 of 82 nM specifically for STAT5b and 1.7 μM for STAT5a. This compound is critical for studies exploring the role of STAT5b in various biological processes, including cell proliferation and survival. Although Stafib-2 exhibits limited cell permeability, it remains a valuable tool for researchers investigating signaling pathways associated with STAT5b in cancer and other diseases. -
STAT3 Inhibitor
5-FAM-GpYLPQTV-NH2 is a fluorescently labeled peptide that inhibits the signal transducer and activator of transcription 3 (STAT3). This compound exhibits significant biological activity as a STAT3 inhibitor, making it a valuable tool for cancer research. Its fluorescent properties enable easy tracking in various biological assays, facilitating the study of STAT3-mediated pathways in tumor biology. -
STAT5 Inhibitor
HODHBt is a STAT5 inhibitor that disrupts the interaction between STAT5 and SUMO, thereby preventing the SUMOylation of phosphorylated STAT5. This action enhances IL-15 signaling, which significantly improves the cytotoxicity and functionality of natural killer (NK) cells, as well as promotes the generation of cytokine-induced memory-like (CIML) NK cells. HODHBt is valuable for research into HIV infection and cancer therapies. -
STAT6 Inhibitor
PM-81I is a potent inhibitor of STAT6, targeting its SH2 structural domain to effectively reduce STAT6 phosphorylation levels. This compound serves as a valuable tool in research related to allergic lung diseases, allergic rhinitis, chronic obstructive pulmonary disease, and various cancer studies. Its ability to modulate STAT6 activity makes it relevant for elucidating the molecular mechanisms underlying these conditions.
